Age matters in IUI treatment, but a person’s age alone cannot tell them whether IUI will work.
In general, the chance of pregnancy and live birth declines as the age of the person providing the egg increases. However, IUI success also depends on why pregnancy has not occurred, whether at least one fallopian tube can function, ovulation, ovarian response, sperm quality, the treatment protocol and previous treatment history.
This is why two people of the same age can have very different chances with intrauterine insemination.
It is also why any website presenting one percentage as “your IUI success rate” without explaining the population, treatment protocol and outcome being measured should be interpreted cautiously.
At Slavica IVF & Research Center in Kathmandu, IUI is among the centre’s listed fertility treatments.
For an explanation of what happens before and during treatment, see Slavica’s step-by-step guide to the IUI procedure.
Yes.
Female age is one of the most important predictors of fertility. ASRM states that female age is the single most important predictor of fecundity, while ACOG explains that fertility declines gradually from the early 30s and more rapidly during the mid-to-late 30s.
The same pattern appears in IUI studies.
However, there is no scientifically responsible universal table saying:
“At age 34 your chance is exactly X%, and at age 38 it is exactly Y%.”
The actual probability depends on who was included in the study and what “success” meant.
Before comparing percentages, ask what outcome was measured.
An IUI study may report:
Pregnancy rate: a pregnancy detected after treatment.
Clinical pregnancy rate: generally a pregnancy confirmed clinically, often by ultrasound according to the study definition.
Live-birth rate: treatment resulting in a live birth.
Per-cycle rate: the outcome from one treatment cycle.
Cumulative rate: the chance observed across several attempts.
These numbers should not be treated as interchangeable.
A clinic saying “20% success” without explaining the outcome and denominator has not given you enough information to compare its result meaningfully with another clinic.
For patients, live birth is usually the most clinically meaningful endpoint, but many publications and clinic pages report pregnancy instead.
One large study examining more than 4,100 clomiphene-IUI cycles reported pregnancy rates per initiated cycle that declined progressively with age:
| Age | Pregnancy rate per initiated cycle in this study |
|---|---|
| Under 35 | 10.1% |
| 35–37 | 8.2% |
| 38–40 | 6.5% |
| 41–42 | 3.6% |
| Over 42 | 0.8% |
These numbers come from one particular patient population and treatment protocol. They are not universal IUI success rates and should not be interpreted as Slavica IVF’s results.
More recent evidence shows the same overall age relationship.
A 2024 cohort involving 10,415 insemination cycles found that cumulative live-birth rates declined significantly with increasing maternal age, both for partner-sperm and donor-sperm IUI.
For women aged 40 and older, a systematic review of 42 studies found that live-birth rates per IUI cycle using partner sperm ranged from 0% to 8.5%, with most studies reporting 4% or less.
The useful conclusion is therefore not that everyone in an age band has one fixed probability.
It is:
Age changes the expected value of spending another reproductive cycle on IUI, which makes treatment reassessment increasingly important as age rises.
IUI changes sperm placement and can be combined with treatment that supports ovulation, but it does not reverse biological changes in the eggs.
With increasing reproductive age:
ACOG notes that both egg quantity and egg quality decline with age, while ASRM similarly describes an age-related decline in pregnancy and live-birth probability.
IUI cannot bypass egg quality in the way people sometimes imagine.
Fertilisation after IUI still needs to occur inside the reproductive tract.
IUI is not equally useful for every diagnosis.
For selected couples with unexplained infertility, ASRM recommends ovarian stimulation with oral medication plus IUI as an initial treatment strategy, commonly for three or four cycles before IVF is considered if pregnancy has not occurred.
That recommendation applies to a defined diagnosis. It should not be converted into a rule that every fertility patient must try four IUIs.
Other conditions can substantially change the treatment decision.
IUI does not bypass blocked fallopian tubes.
Prepared sperm is placed inside the uterus, but fertilisation still generally needs to occur in a fallopian tube.
For this reason, assessment of the reproductive tract and tubal patency can be relevant before IUI. ASRM includes tubal evaluation within a standard infertility work-up and recommends HSG or sonohysterography as methods of evaluating tubal patency.
If both tubes are blocked, repeatedly placing sperm into the uterus does not solve the underlying barrier.
IUI also depends on having enough usable motile sperm after laboratory processing.
The joint AUA/ASRM male-infertility guideline states that couples with repeatedly low total motile sperm counts should be counselled that IUI success can be reduced. It specifically notes limited chances when fewer than about 5 million motile sperm remain after processing.
That number is not a self-diagnosis threshold.
A semen report needs to be interpreted together with the age and fertility factors of the other partner.
For a more detailed explanation, see Slavica’s semen analysis interpretation guide.
Some IUI cycles occur around spontaneous ovulation. Others use medication to stimulate or support follicular development.
Treatment protocol can affect both pregnancy probability and risk.
For unexplained infertility, ASRM finds ovarian stimulation with oral agents plus IUI more effective than natural-cycle IUI, but stimulation also needs appropriate monitoring because developing multiple follicles can increase the risk of multiple pregnancy.
More medication therefore does not automatically mean a better treatment plan.
Patients frequently assume:
“My AMH is good, so my IUI success rate must be high.”
AMH does not work that way.
Ovarian reserve testing can help fertility specialists estimate ovarian response and plan treatment, but ASRM states that ovarian reserve tests should augment rather than replace counselling based on age and diagnosis.
AMH primarily provides information about ovarian reserve. It is not a direct measurement of egg quality and cannot guarantee pregnancy.
Slavica has a dedicated guide explaining what low AMH can and cannot tell you about fertility.
A failed first IUI does not automatically mean IUI cannot work.
At the same time, repeating treatment indefinitely is not evidence-based.
For selected unexplained-infertility patients, ASRM’s commonly recommended sequence is approximately three or four cycles of oral-agent ovarian stimulation plus IUI, followed by IVF if pregnancy has not occurred.
Treatment should sometimes be reconsidered earlier because of:
The important decision is therefore not:
“How many IUIs is everyone supposed to do?”
It is:
“How many attempts are reasonable for us before the probability, time and cost no longer justify continuing?”
There is not currently enough verified national outcome data to responsibly state that Nepal has one universal IUI success rate.
One peer-reviewed Nepal study published in 2023 reviewed 225 women receiving IUI at a fertility centre in Lalitpur. Pregnancy occurred in 23 women, or 10.22% of the study population. The mean age among those who became pregnant was approximately 29 years.
That study is useful because it provides local evidence.
But it should not be interpreted as:
Current Nepal clinic websites also publish varying figures, reinforcing why patients should ask exactly how a quoted success rate was calculated.
If a fertility clinic provides a percentage, ask:
Is this pregnancy or live birth?
Is it per IUI cycle or per patient?
Which age group does it represent?
Are cancelled cycles included?
Does it include donor sperm?
Which treatment protocol was used?
Those questions make the statistic far more meaningful.
There is no universal number.
For many couples with unexplained infertility and a favourable prognosis, a limited course of IUI can be reasonable.
ASRM recommends approximately three or four cycles of ovarian stimulation with oral agents plus IUI for many couples with unexplained infertility, followed by IVF when that strategy is unsuccessful.
But age changes the calculation.
A younger person with open tubes, favourable sperm findings and unexplained infertility may reasonably have more time to pursue a limited IUI course.
Someone approaching 40 may value reproductive time differently because every additional month occurs against a steeper age-related fertility decline.
That is why the appropriate number of IUI attempts should be discussed before the first cycle, not only after several failures.
IUI should be reconsidered when the expected benefit of another cycle becomes too low relative to the time, cost and emotional burden involved.
Reasons for earlier review may include:
For unexplained infertility specifically, ASRM reports good evidence that immediate IVF in women aged 38 and older may provide a higher pregnancy rate and shorter time to pregnancy than a strategy involving ovarian-stimulation IUI before IVF.
That does not mean every 38-year-old automatically needs IVF.
It means age should influence how long lower-probability treatment is continued.
For a fuller comparison, see Slavica’s IVF vs IUI guide.
It can be.
Age 35 is not a switch that makes IUI ineffective overnight.
However, fertility decline becomes increasingly relevant during the mid-to-late 30s. ASRM recommends infertility evaluation after six months of trying to conceive for women aged 35 or older, compared with 12 months for younger women without another reason for earlier evaluation.
An IUI plan after 35 should therefore consider not only whether treatment is technically possible but also whether it is the most efficient strategy for the individual’s diagnosis and reproductive goals.
Pregnancy through IUI after 40 remains possible, but expectations should be considerably more cautious.
A systematic review focusing on women aged 40 and older found that partner-sperm IUI live-birth rates per cycle were generally low, with most included studies reporting no more than about 4%. IVF produced higher live-birth rates in the studies that directly compared the two strategies.
ASRM also advises that women older than 40 may warrant more immediate fertility evaluation and treatment rather than waiting through the timelines used for younger patients.
The question at this stage becomes less:
“Can IUI ever work?”
and more:
“Is another IUI cycle the best use of my available reproductive time?”
That conversation needs to be individual.
Before repeating treatment, ask your fertility specialist:
These questions turn “try again” into an informed treatment decision.
Slavica IVF & Research Center lists intrauterine insemination, ovulation induction, follicular monitoring, semen analysis, ovarian reserve testing, IVF and ICSI among its fertility services in Sinamangal, Kathmandu.
For patients considering treatment, the useful starting point is not choosing IUI from an age chart.
It is determining:
You can review Slavica’s intrauterine insemination service and its guide to IUI treatment cost in Nepal.
If you already have fertility test results or previous IUI records, bring them to your consultation so the treatment team can assess the complete history rather than estimating your chances from age alone.
There is no single percentage that defines a “good” IUI result. It depends on the patient’s age, diagnosis, sperm source and quality, treatment protocol and whether the clinic is reporting pregnancy or live birth. Always ask how the percentage was calculated.
Cumulative chances can increase across repeated appropriately selected cycles because each attempt creates another opportunity for pregnancy. However, an individual cycle does not necessarily become more biologically successful merely because it is the second or third attempt.
For unexplained infertility, ASRM finds that ovarian stimulation using oral agents combined with IUI is more effective than natural-cycle IUI. Medication also changes risks, especially the possibility of multiple follicle development, so treatment should be monitored.
No. AMH helps assess ovarian reserve and potential response to stimulation but does not directly measure egg quality or guarantee pregnancy. Age and diagnosis remain essential when interpreting ovarian reserve results.
Sometimes, depending on the severity and the number of motile sperm available after processing. AUA/ASRM guidance notes that IUI pregnancy rates can be reduced with persistently low total motile sperm counts and become particularly limited when the post-processing total is below approximately 5 million.
No. One unsuccessful cycle alone does not determine the next treatment. The decision depends on age, diagnosis, ovarian response, sperm findings, tubal status and previous fertility history.
There is no universal age at which every patient must skip IUI. However, the expected benefit declines substantially with age, and evidence supports earlier discussion of IVF particularly around the late 30s and 40s when reproductive time is more limited.
